Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Baird Maintains Outperform on Frequency Therapeutics, Lowers Price Target to $4

Baird Maintains Outperform on Frequency Therapeutics, Lowers Price Target to $4

Baird analyst Jack Allen maintains Frequency Therapeutics (NASDAQ:FREQ) with a Outperform and lowers the price target from $10 to $4.

byBenzinga Newsdesk

February 14, 2023

1 minute read

Baird analyst Jack Allen maintains Frequency Therapeutics (NASDAQ:FREQ) with a Outperform and lowers the price target from $10 to $4.

Sanofi’s $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information

By Vandana Singh

April 11, 2:14 PM

Sanofi SA (NASDAQ:SNY) withdrew and refiled the Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act “following…

PRVB

Analyst Ratings

Analyst Ratings for Taylor Morrison Home

By Benzinga Insights

June 28, 4:00 PM

Within the last quarter, Taylor Morrison Home (NYSE:TMHC) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent…

TMHC

Analyst Ratings

What Analysts Are Saying About GLOBALFOUNDRIES Stock

By Benzinga Insights

February 14, 10:00 AM

GLOBALFOUNDRIES (NASDAQ:GFS) has been analyzed by 5 analysts in the last three months, revealing a diverse range of…

GFS

Credit Suisse Maintains Outperform on Cigna, Raises Price Target to $368

By Benzinga Newsdesk

November 7, 8:42 AM

Credit Suisse analyst Jonathan Yong maintains Cigna (NYSE:CI) with a Outperform and raises the price target from $329 to $368.

Baird Maintains Outperform on Frequency Therapeutics, Lowers Price Target to $4

Related Posts

Sanofi’s $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information

Analyst Ratings for Taylor Morrison Home

What Analysts Are Saying About GLOBALFOUNDRIES Stock

Credit Suisse Maintains Outperform on Cigna, Raises Price Target to $368